Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 1725354, 8 pages
https://doi.org/10.1155/2017/1725354
Research Article

Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population

1Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China
2Department of Respiration Medicine, The Third People’s Hospital of Cixi, Ningbo 315324, China
3Department of Pathology, Zhejiang Provincial People’s Hospital, Hangzhou 310014, China
4School of Medicine, Hangzhou Normal University, Hangzhou 310016, China

Correspondence should be addressed to Jianlin Lou; moc.361@uolnilnaij

Zhaoqiang Jiang and Shibo Ying contributed equally to this work.

Received 17 June 2017; Accepted 2 October 2017; Published 22 October 2017

Academic Editor: Lance A. Liotta

Copyright © 2017 Zhaoqiang Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, Environmental Health Criteria 203: Chrysotile Asbestos, World Health Organization, Geneva, 1998.
  2. M. R. Harbut, “Treatment of nonmalignant asbestos-related diseases,” American Journal of Industrial Medicine, vol. 50, no. 1, pp. 71-72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Diandini, K. Takahashi, E. K. Park et al., “Potential years of life lost (PYLL) caused by asbestos-related diseases in the world,” American Journal of Industrial Medicine, vol. 56, no. 9, pp. 993–1000, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Algranti, E. M. Mendonca, E. M. DeCapitani, J. B. Freitas, H. C. Silva, and M. A. Bussacos, “Non-malignant asbestos-related diseases in Brazilian asbestos-cement workers,” American Journal of Industrial Medicine, vol. 40, no. 3, pp. 240–254, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Mesaros, A. J. Worth, N. W. Snyder et al., “Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure,” Bioanalysis, vol. 7, no. 9, pp. 1157–1173, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. N. Courtice, S. Lin, and X. Wang, “An updated review on asbestos and related diseases in China,” International Journal of Occupational and Environmental Health, vol. 18, no. 3, pp. 247–253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. C. Haynes, “A worn-out welcome: renewed call for a global ban on asbestos,” Environmental Health Perspectives, vol. 118, no. 7, pp. A298–A303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Wang, E. Yano, S. Lin et al., “Cancer mortality in Chinese chrysotile asbestos miners: exposure-response relationships,” PLoS One, vol. 8, no. 8, article e71899, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Panou, M. Vyberg, U. M. Weinreich, C. Meristoudis, U. G. Falkmer, and O. D. Roe, “The established and future biomarkers of malignant pleural mesothelioma,” Cancer Treatment Reviews, vol. 41, no. 6, pp. 486–495, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. J. D. Hulleman, “Malattia Leventinese/Doyne honeycomb retinal dystrophy: similarities to age-related macular degeneration and potential therapies,” Advances in Experimental Medicine and Biology, vol. 854, pp. 153–158, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Xu, Y. Yang, Y. B. Sun, H. Y. Wang, C. B. Sun, and X. Zhang, “Role of fibulin-3 in lung cancer: in vivo and in vitro analyses,” Oncology Reports, vol. 31, no. 1, pp. 79–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Sadr-Nabavi, J. Ramser, J. Volkmann et al., “Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker,” International Journal of Cancer, vol. 124, no. 7, pp. 1727–1735, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Luo, M. Zhang, L. Liu, S. Lu, C. Z. Zhang, and J. Yun, “Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis,” PLoS One, vol. 8, no. 8, article e70511, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. H. I. Pass, Z. Liu, A. Wali et al., “Gene expression profiles predict survival and progression of pleural mesothelioma,” Clinical Cancer Research, vol. 10, no. 3, pp. 849–859, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Tsim, C. Kelly, L. Alexander et al., “Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study,” BMJ Open, vol. 6, no. 11, article e013324, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. H. I. Pass, S. M. Levin, M. R. Harbut et al., “Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma,” The New England Journal of Medicine, vol. 367, no. 15, pp. 1417–1427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. B. Kirschner, E. Pulford, M. A. Hoda et al., “Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis,” British Journal of Cancer, vol. 113, no. 6, pp. 963–969, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Ying, Z. Jiang, X. He et al., “Serum HMGB1 as a potential biomarker for patients with asbestos-related diseases,” Disease Markers, vol. 2017, Article ID 5756102, 9 pages, 2017. View at Publisher · View at Google Scholar
  19. American Thoracic Society, “Diagnosis and initial management of nonmalignant diseases related to asbestos,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 6, pp. 691–715, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. N. Husain, T. Colby, N. Ordonez et al., “Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group,” Archives of Pathology & Laboratory Medicine, vol. 137, no. 5, pp. 647–667, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Yu, Y. Zhang, Z. Jiang et al., “Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population,” Environmental Health and Preventive Medicine, vol. 20, no. 5, pp. 369–378, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Ortega-Guerrero, G. Carrasco-Nunez, H. Barragan-Campos, and M. R. Ortega, “High incidence of lung cancer and malignant mesothelioma linked to erionite fibre exposure in a rural community in Central Mexico,” Occupational and Environmental Medicine, vol. 72, no. 3, pp. 216–218, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Prazakova, P. S. Thomas, A. Sandrini, and D. H. Yates, “Asbestos and the lung in the 21st century: an update,” The Clinical Respiratory Journal, vol. 8, no. 1, pp. 1–10, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. E. K. Park, D. H. Yates, J. Creaney, P. S. Thomas, B. W. Robinson, and A. R. Johnson, “Association of biomarker levels with severity of asbestos-related diseases,” Safety and Health at Work, vol. 3, no. 1, pp. 17–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. H. I. Pass, D. Lott, F. Lonardo et al., “Asbestos exposure, pleural mesothelioma, and serum osteopontin levels,” The New England Journal of Medicine, vol. 353, no. 15, pp. 1564–1573, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Cui, X. G. Jin, K. Zhai, Z. H. Tong, and H. Z. Shi, “Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis,” BMJ Open, vol. 4, no. 2, article e004145, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Cristaudo, A. Bonotti, S. Simonini et al., “Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma,” Journal of Thoracic Oncology, vol. 6, no. 9, pp. 1587–1593, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Hollevoet, K. Nackaerts, J. Thimpont et al., “Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 6, pp. 620–625, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Corradi, M. Goldoni, R. Alinovi et al., “YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis,” Anticancer Research, vol. 33, no. 12, pp. 5517–5524, 2013. View at Google Scholar
  30. A. Lacourt, P. Rolland, C. Gramond et al., “Attributable risk in men in two French case-control studies on mesothelioma and asbestos,” European Journal of Epidemiology, vol. 25, no. 11, pp. 799–806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Hu, P. D. Pioli, E. Siegel et al., “EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment,” Molecular Cancer, vol. 10, p. 123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. J. Obaya, S. Rua, A. Moncada-Pazos, and S. Cal, “The dual role of fibulins in tumorigenesis,” Cancer Letters, vol. 325, no. 2, pp. 132–138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Tian, J. Liu, J. Chen, M. L. Gatza, and G. C. Blobe, “Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment,” Oncogene, vol. 34, no. 45, pp. 5635–5647, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. I. G. Kim, S. Y. Kim, S. I. Choi, J. H. Lee, K. C. Kim, and E. W. Cho, “Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling,” Oncogene, vol. 33, no. 30, pp. 3908–3917, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. X. Chen, J. Meng, W. Yue et al., “Fibulin-3 suppresses Wnt/β-catenin signaling and lung cancer invasion,” Carcinogenesis, vol. 35, no. 8, pp. 1707–1716, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Kovac, M. Dodic-Fikfak, N. Arneric, V. Dolzan, and A. Franko, “Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma,” Radiology and Oncology, vol. 49, no. 3, pp. 279–285, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Creaney, I. M. Dick, T. M. Meniawy et al., “Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma,” Thorax, vol. 69, no. 10, pp. 895–902, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. E. K. Park, K. Takahashi, T. Hoshuyama et al., “Global magnitude of reported and unreported mesothelioma,” Environmental Health Perspectives, vol. 119, no. 4, pp. 514–518, 2011. View at Publisher · View at Google Scholar · View at Scopus